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and K. S. Rangappa*gHepatocellular carcinoma, a fatal liver cancer, aﬀects 600 000 people
annually and ranks third in cancer-related lethality. In this work we
report the synthesis and related biological activity of novel dihy-
dropyrimidones. Among the tested compounds, 5-acetyl-4-(1H-
indol-3-yl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (4g) was found
to bemost active towards the HepG2 cell line (IC50¼ 17.9 mM), being at
the same time 7.6-fold selective over normal (LO2) liver cells (IC50 ¼
136.9 mM). Subsequently, we identiﬁed peroxisome proliferator-acti-
vated receptor g as a target of compound 4g using an in silico
approach, and conﬁrmed this mode-of-action experimentally.The peroxisome proliferator-activated receptor (PPAR) belongs
to the nuclear hormone receptor superfamily of transcription
factors that includes 48 human transcription factors. Its activity
is regulated by direct binding of steroid and thyroid hormones,
vitamins, lipid metabolites, and xenobiotics.1 PPARs hetero-
dimerize with retinoid X receptors, which get activated and bind
to specic response elements in the target DNA of various targetent of Chemistry, Bangalore University,
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hemistry 2014genes,2,3 PPARs consist of three diﬀerent isoforms, PPAR-a,
PPAR-b/d, and PPAR-g. Due to their central function in a variety
of physiological processes, PPARs are important targets in drug
discovery.4 Small molecules frequently interact with more than
a single PPAR isoform leading to unique proles of their bio-
logical eﬀects.5
In particular, PPAR-g has been established as a key regulator
for inammation,6 proliferation,7 metabolism,8 and diﬀerenti-
ation,9 and it is also upregulated by many tumor suppressor
genes.10 PPAR-g is overexpressed in several types of human
cancers, including breast, colon, bladder, and prostate cancer,
and it also induces apoptosis in several malignant cell line-
ages.11 Furthermore, PPAR-g ligands such as 15d-PGJ2 as well as
antidiabetic thiazolidinediones (TZDs) function as anti-prolif-
erative and proapoptotic agents, suggesting that PPAR-g could
be a promising therapeutic target for the treatment of
cancer.12–14 Non-thiazolidinedione derivatives, such as 2-cyano-
3,12-dioxooleana-1,9-dien-28-oic acid, GW-7845, JTT-501, KRP-
297, L-764406, MCC-555 and GW-0207 are further known
synthetic ligands of PPAR-g.15
On the other hand, the natural product ectoine, a tetrahy-
dropyrimidine derivative, oﬀers protection against the eﬀects of
ischemia-reperfusion injury in intestinal transplantation in vivo.16
()-Aplicyanin analogs bearing a pyrimidone moiety showed
signicant anti-tumor activity via targeting p38 MAP kinase.17–19
Similar small molecules, dihydropyrimidines (DHPs), have
also been reported as anti-cancer agents.20 Recently, pyrimi-
dine-tethered curcumins showed anticancer activity by target-
ing EGFR tyrosine kinase.21
In continuation of our interest to synthesize novel bioactive
heteocycles,22–24 we herein report the synthesis of DHP tethered
to various functional heterocycles like indole, avone and
benzofuran. Furthermore, and conceptually rather novel, we
rationalized the mode-of-action for the lead DHP as PPAR-g via
an in silico cheminformatics approach, followed by experi-
mental validation. Details on synthesis, compound chararacte-
rization, biological assays, and in silico methods are described
in more detail in the ESI.†RSC Adv., 2014, 4, 45143–45146 | 45143
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View Article OnlineFor synthesis, multi-component reactions (MCRs) have been
employed which constitute an eﬃcient synthetic strategy for
rapid and eﬀective laboratory organic transformations, because
products are prepared in a one-pot and single step approach and
the diversity can be obtained directly by changing the reacting
components.25 Here, we synthesized the dihydropyrimidone
bearing small molecules via multi-component Biginelli reac-
tion.26 The mechanism for the formation of the title compounds
involves the condensation between the aldehyde and urea to
form an iminium intermediate, which acts as electrophile for the
nucleophilic addition of the ketoester enol, and the ketone
carbonyl of the resulting adduct undergoes condensation with
the amine group of urea to give the cyclized product (Fig. 1A).
Also further heterocycles such as indole, avone and benzofuran
moieties were successful employed for the preparation of novel
dihydropyrimidones (see ESI Table 1†). The protocol was eﬀec-
tive with aromatic amines having electron donating groups, and
products were identied based on IR, LCMS, 1H NMR, and 13C
NMR spectra (see ESI†). In the next step, the cytotoxic eﬀects of
dihydropyrimidones was investigated in HepG2 cell lines using
the MTT assay. The cells were treated with 0, 10, 25, 50, and 100
mM concentrations of dihydropyrimidones for 72 h. DHPs were
found to inhibit the viability of HepG2 cells in a dose-and time-
dependent manner. Compound 4g, 4k and 4p were found to be
most eﬀective with IC50 values less than 50 mM. In addition, we
were able to identify that all the dihydropyrimidone series of
compounds inhibited the viability of immortalized normal
human liver cells, LO2, at higher concentrations. Compound 4g
was found have an IC50 value of 17.9 mM against HepG2 and has
the highest, 7.6-fold selectivity over the normal LO2 liver cell line
(IC50 ¼ 136.93 mM; see ESI Table 2† for more details). Therefore,
we considered 4g (Fig. 1B) in more detail and studied its mode-
of-action in HepG2 cells.Fig. 1 Synthetic scheme of novel dihydropyrimidones and cytotoxicity
studies for the lead compound 4g against various HCC cells.
45144 | RSC Adv., 2014, 4, 45143–45146Human protein targets were predicted for the most bioactive
compound 4g, and of all predicted targets (ESI Table 3†), PPAR-
g was the only target with score of 26.02, exceeding the signif-
icance cut-oﬀ of 10. Given the involvement of PPAR-g in the
induction of apoptosis and cancer development, as described in
previous studies,4–6 this target was selected for further analysis.
PPAR-g has been extensively shown to be associated with
anti-cancer eﬀects in a variety of cancer types including HCC.
HepG2 cells were treated with diﬀerent concentrations of
compound 4g for 8 h and then analyzed for the expression of
PPAR-g by western blot analysis. It was found that compound 4g
could substantially increase PPAR-g expression in a dose-
dependent manner, with maximum eﬀect at 15 mM concentra-
tion (Fig. 2A). Compound 4g also increased PPAR-g expression
in a time-dependent manner, with maximum activity at 8 h
(Fig. 2B). Evidently, the DNA-binding assay for PPAR-g in
nuclear extracts showed that compound 4g signicantly
enhanced PPAR-g DNA binding ability in a time dependent
manner (Fig. 2C).
DHPs are well known ligands for PPAR-g. In order to deter-
mine the interaction of dihydropyrimidones towards PPAR-g,
the co-crystal structure of human PPAR-g in complex with
rosiglitazone was considered for our studies.27 Using Discovery
Studio (DS) default tools and settings, the ligand binding
domain (LBD) of PPAR-g was identied and ligands were
prepared for docking utilizing the CDOCKER programme of the
ligand–receptor interaction module of Discovery Studio version
2.5, the dihydropyrimidones were docked into the LBD of PPAR.
The CDOCKER energies for all docked ligands (ESI Table 4†)
indicate that compound 4g bound to the LBD region with the
lowest (and thus most favorable) score of 24.0 kcal mol1 (ESI
Table 3†). Furthermore, the binding pose of compound 4g was
found to overlap with the hydrophobic tail of TZDs (rosiglita-
zone; Fig. 2D). Compound 4g forms mainly hydrophobic
contacts with residues at the LBD region of PPAR-g includingFig. 2 In silico and in vitro rationalization of the mode-of-action
analysis for the lead compound 4g that targets PPAR-g in HepG2 cells.
This journal is © The Royal Society of Chemistry 2014
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View Article OnlineIle281, Met348, Ile353, Val339, Cys285, Ile341, Ser342, Gly284,
Tyr321, Ile326, Lys367, Phe363, Met364, Leu330, Ser289, and
Arg288 (Fig. 2E). Thereby, CH–p interactions with Leu-330 and
van der Waals contacts with the alkyl chain of Arg-288 are
proposed as main driving forces of the ligand. This molecular
docking study revealed that compound 4g could be a suitable
non-TZD ligand for PPAR-g.
We investigated whether activation of PPAR-g in HepG2 cells
by compound 4g leads to apoptosis. In HepG2 cells treated with
compound 4g, there was a time-dependent reduction in the
levels of procaspase-3 (Fig. 3A). This suggests that cleavage
events had occurred, indicating the activation of caspase-3, the
levels of which were shown to be increased aer 48 h. Activation
of caspase-3 led to the cleavage of a 118 kDa Poly (ADP-ribose)
polymerase (PARP) protein into an 85 kDa fragment (Fig. 3B).
This result clearly suggests that compound 4g induces caspase-
3-dependent apoptosis in HepG2 cells. In addition, compound
4g was found to downregulate the anti-apoptotic and prolifer-
ative proteins, Bcl-2 and Cyclin D1 in a time dependent manner
(Fig. 3C), with maximum eﬀect observed at 48 h. Pronounced
expression of PPAR-g was demonstrated in HCC cells treated
with rosiglitazone and such induction markedly suppressed the
migration of HCC cells.28 The eﬀect of compound 4g on the
migration of HepG2 cells was investigated using a wound
healing assay. We found that compound 4g treatment signi-
cantly suppressed the migration of HepG2 cells, and the
pretreatment with GW9662, a pharmacological PPAR-g inhib-
itor, reversed the anti-migratory eﬀects of compound 4g as
shown in Fig. 3D and E. It is well known that PPAR-g ligands
may have therapeutic value for the treatment of highly invasive
breast cancer by targeting invasion.29 An in vitro Bio-Coat
Matrigel invasion assay was performed (BD Biosciences, San
Jose, CA, USA), and it was found that upon treatment with
compound 4g there was a signicant reduction in the number
of cells that could invade the Matrigel coated polycarbonateFig. 3 Apoptotic induction, anti-migration, and anti-invasive activity
of the compound 4g in HCC cells.
This journal is © The Royal Society of Chemistry 2014membrane, indicating that compound 4g could indeed signi-
cantly inhibit the invasive property of HepG2 cells (Fig. 3F and
G). Moreover, we found that pretreatment with the PPAR-g
antagonist GW9662 reversed the anti-invasive potential of
compound 4g in HCC cells, conrming that the activity is
mediated through inhibition of PPAR-g pathway.
In conclusion, we herein report the synthesis of novel dihy-
dropyrimidones and found 5-acetyl-4-(1H-indol-3-yl)-6-methyl-
3,4-dihydropyrimidin-2(1H)-one (4g) to be most active against
HCC cells. Furthermore, compound 4g down-regulated anti-
apoptotic and proliferative proteins such as Bcl-2 and Cyclin D1
in a time-dependent manner. In silico studies predicted PPAR-g
as mode-of-action of compound 4g, which could be validated by
in vitro studies. Molecular docking furthermore suggested the
binding pose of 4g within the ligand binding domain of PPAR-g,
which overlaps with the tail of rosiglitazone. Compound 4g
inhibited the invasive property of HepG2 cells and the
pretreatment with GW9662 reversed the anti-invasive potential
of compound 4g in HCC cells in vitro, thereby conrming that
the activity is mediated through inhibition of PPAR-g pathway.
Hence, both in silico and experimental methods agree on the
mode-of-action of compound 4g via PPAR-g.
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